There is longstanding evidence that CD26 expression has been characterized in various tumors. Thus, CD26 has been extensively studied as a potential therapeutic target and a tumor biomarker in various malignancies. With advanced and high-end technologies, rich experienced scientists, Creative Biolabs is an excellent service provider in the field of tumor marker assay. After long years ahead to fully comprehend tumor markers, we launch our CD26 assay portfolio service which can be useful for targeted cancer therapy and diagnosis.
Fig.1 Band structure of human CD26. (From Wikipedia)
CD26, known as dipeptidyl peptidase IV (DPP4 or DPPIV), is expressed as a type II transmembrane protein with proteolytic activity capable of cleaving N-terminal dipeptides from polypeptides with proline or alanine in the penultimate position and is a member of prolyl peptidase family. It is active as a dimer with a monomer molecular weight of 110 kDa and is widely expressed in most cell types including endothelial, epithelial, and T lymphocytes cells.
Given these functions, CD26 is involved in tumorigenesis and may serve as a tumor suppressor or activator, depending on its tumor microenvironment.
CD26 expression has been characterized on various cancers, such as colorectal cancer, lung cancer, prostate cancer, malignant pleural mesothelioma, gastrointestinal stromal tumor, and selected hematologic malignancies.
Research has shown that in cell lines with low CD26 expression and activity, the SDF-1 acts via the activation of CXCR4 receptor, stimulating cell invasion, migration, and proliferation, besides promoting metastasis. But the malignant phenotype can be reverted when CD26 expression is induced in these cells. However, based on tumor type, different cell signaling pathways can be activated.
Fig.2 The role of CD26 in different types of cancer. (Beckenkamp, 2016)
If you are interested in our service, please contact us or directly send us.
For Research Use Only | Not For Clinical Use
Download our brochure